Showing 13 to 23 of 23 results
FDA Mandates Updated Covid-19 Vaccine Warning Labels
The FDA mandates updated Covid-19 vaccine warning labels for Pfizer-BioNTech and Moderna, specifying a slightly increased risk of myocarditis/pericarditis in males aged 16-25 based on health insurance claims data analysis showing 38 cases per million doses, highlighting the importance of transparenc...
FDA Mandates Updated Covid-19 Vaccine Warning Labels
The FDA mandates updated Covid-19 vaccine warning labels for Pfizer-BioNTech and Moderna, specifying a slightly increased risk of myocarditis/pericarditis in males aged 16-25 based on health insurance claims data analysis showing 38 cases per million doses, highlighting the importance of transparenc...
Progress
48% Bias Score
Moderna Stock Drops 36% Amidst Falling COVID-19 Vaccine Demand
Moderna (MRNA) stock has fallen 36% this year due to decreased demand for its COVID-19 vaccine, resulting in a 52.6% revenue drop in the last twelve months; however, the company's strong balance sheet and promising vaccine pipeline offer potential for a future turnaround.
Moderna Stock Drops 36% Amidst Falling COVID-19 Vaccine Demand
Moderna (MRNA) stock has fallen 36% this year due to decreased demand for its COVID-19 vaccine, resulting in a 52.6% revenue drop in the last twelve months; however, the company's strong balance sheet and promising vaccine pipeline offer potential for a future turnaround.
Progress
36% Bias Score
mRNA Cancer Vaccines: Promising Trials, but No Approvals Yet
Despite initial hopes after the success of mRNA COVID-19 vaccines, no mRNA cancer vaccines have received approval yet; however, several are in clinical trials, showing potential for personalized cancer treatments but facing significant hurdles.
mRNA Cancer Vaccines: Promising Trials, but No Approvals Yet
Despite initial hopes after the success of mRNA COVID-19 vaccines, no mRNA cancer vaccines have received approval yet; however, several are in clinical trials, showing potential for personalized cancer treatments but facing significant hurdles.
Progress
32% Bias Score
Moderna Receives $590 Million for Accelerated Bird Flu Vaccine Development
The U.S. government awarded Moderna an additional $590 million to expedite development of an mRNA bird flu vaccine, bringing the total to $766 million, aiming to expand clinical trials for five subtypes and enhance pandemic preparedness amid 67 confirmed human cases since April 2024, with one death ...
Moderna Receives $590 Million for Accelerated Bird Flu Vaccine Development
The U.S. government awarded Moderna an additional $590 million to expedite development of an mRNA bird flu vaccine, bringing the total to $766 million, aiming to expand clinical trials for five subtypes and enhance pandemic preparedness amid 67 confirmed human cases since April 2024, with one death ...
Progress
36% Bias Score
Three Undervalued Stocks for 2025: Intel, Moderna, and Walgreens
The author analyzes three underperforming stocks—Intel, Moderna, and Walgreens—highlighting their potential for recovery despite 2024 losses due to factors like government subsidies, future drug pipelines, and cost-cutting strategies.
Three Undervalued Stocks for 2025: Intel, Moderna, and Walgreens
The author analyzes three underperforming stocks—Intel, Moderna, and Walgreens—highlighting their potential for recovery despite 2024 losses due to factors like government subsidies, future drug pipelines, and cost-cutting strategies.
Progress
36% Bias Score
Moderna Vaccine Deal Bypasses Australian Assessment
Australia's $2 billion deal with Moderna for onshore mRNA vaccine manufacturing bypasses the Pharmaceutical Benefits Advisory Committee (PBAC) assessment, raising concerns about transparency and cost-effectiveness, prompting an investigation and criticism from health experts and competitors.
Moderna Vaccine Deal Bypasses Australian Assessment
Australia's $2 billion deal with Moderna for onshore mRNA vaccine manufacturing bypasses the Pharmaceutical Benefits Advisory Committee (PBAC) assessment, raising concerns about transparency and cost-effectiveness, prompting an investigation and criticism from health experts and competitors.
Progress
52% Bias Score
FDA Expands COVID-19 Vaccine Warnings for Myocarditis Risk in Young Men
The FDA is expanding warning labels on Pfizer and Moderna's COVID-19 vaccines to include a higher risk of myocarditis and pericarditis in males aged 16-25, citing a rate of 38 cases per million doses compared to 8 per million in other groups, based on a study published last year and new agency data....
FDA Expands COVID-19 Vaccine Warnings for Myocarditis Risk in Young Men
The FDA is expanding warning labels on Pfizer and Moderna's COVID-19 vaccines to include a higher risk of myocarditis and pericarditis in males aged 16-25, citing a rate of 38 cases per million doses compared to 8 per million in other groups, based on a study published last year and new agency data....
Progress
64% Bias Score
Moderna Stock Surges on Patent Win, but Weak Financials Raise Concerns
Moderna's stock jumped 16% after winning a patent infringement case against BioNTech and Pfizer, but its weak recent financial performance, including a 66% quarterly revenue drop and negative operating margins, raises concerns for investors despite a strong balance sheet.
Moderna Stock Surges on Patent Win, but Weak Financials Raise Concerns
Moderna's stock jumped 16% after winning a patent infringement case against BioNTech and Pfizer, but its weak recent financial performance, including a 66% quarterly revenue drop and negative operating margins, raises concerns for investors despite a strong balance sheet.
Progress
60% Bias Score
Moderna's Norovirus Vaccine Trial Accelerated Amid Severe Winter Outbreak
Moderna's norovirus vaccine is in phase three trials, enrolling ahead of schedule due to a severe winter outbreak, with results expected by late 2024 or 2026. The vaccine targets three common genotypes, aiming to lessen symptoms and hospitalizations in high-risk groups like seniors and healthcare wo...
Moderna's Norovirus Vaccine Trial Accelerated Amid Severe Winter Outbreak
Moderna's norovirus vaccine is in phase three trials, enrolling ahead of schedule due to a severe winter outbreak, with results expected by late 2024 or 2026. The vaccine targets three common genotypes, aiming to lessen symptoms and hospitalizations in high-risk groups like seniors and healthcare wo...
Progress
36% Bias Score
S&P 500's 2024 Gains Mask Significant Underperformance by Key Companies
The S&P 500 index is up 23.8% in 2024, but this masks significant underperformance in some sectors. Walgreens Boots Alliance, Intel, and Moderna are among the worst performers, each losing more than 60% and being replaced in the Dow Jones. These declines are attributed to company-specific challenges...
S&P 500's 2024 Gains Mask Significant Underperformance by Key Companies
The S&P 500 index is up 23.8% in 2024, but this masks significant underperformance in some sectors. Walgreens Boots Alliance, Intel, and Moderna are among the worst performers, each losing more than 60% and being replaced in the Dow Jones. These declines are attributed to company-specific challenges...
Progress
48% Bias Score
Moderna Stock Plunges Amidst Financial Uncertainty and Anti-Vaccine Concerns
Moderna's stock, once a pandemic star, has plummeted 90% from its peak, fueled by concerns over its reliance on the Covid-19 vaccine, an underwhelming RSV vaccine, and the potential impact of anti-vaccine sentiment within the incoming Trump administration.
Moderna Stock Plunges Amidst Financial Uncertainty and Anti-Vaccine Concerns
Moderna's stock, once a pandemic star, has plummeted 90% from its peak, fueled by concerns over its reliance on the Covid-19 vaccine, an underwhelming RSV vaccine, and the potential impact of anti-vaccine sentiment within the incoming Trump administration.
Progress
52% Bias Score
Showing 13 to 23 of 23 results